Phil Hempleman's hedge fund firm Ardsley Partners has filed a 13G with the SEC regarding their position in Bioscrip (BIOS). Per the filing, Ardsley now owns 5.1% of the company with over 3.53 million shares.
They've increased their position size by over 1.9 million shares since the end of the third quarter. The filing was made due to activity on January 29th.
Hempleman founded Ardsley in 1987 and is a long/short equity focused fund that uses bottom-up stockpicking to build its portfolio. We've covered other portfolio activity from Ardsley here.
Per Google Finance, Bioscrip is "provides home infusion and other home healthcare services. The Company’s services are designed to improve clinical outcomes for patients with chronic and acute healthcare conditions while controlling overall healthcare costs. The Company’s platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch, home-based and community-based care environment. Its core services are provided in coordination with, and under the direction of the patients' physicians."
Tuesday, February 10, 2015
Phil Hempleman's Ardsley Partners Adds To Bioscrip
blog comments powered by Disqus
